GeneCentric Therapeutics
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Research Triangle Park PO Box 12838, Dur...Phone Number
(919) 973-6544Website
www.genecentric.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About GeneCentric Therapeutics
GeneCentric Therapeutics, Inc., a leader in gene expression biomarkers and next-generation companion diagnostic development, is based in Durham, North Carolina. The company has developed a deep pipeline of gene signatures and related diagnostic tests by parsing the complexity of tumor biology using their RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform and proprietary AI-based technology to identify responder populations to oncology therapeutics. Along with its ExpressCT technology, these signatures can be applied to liquid biopsy through its GenomicsNext platform. GeneCentric commercializes its technology through strategic collaborations with biopharmaceutical and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases.Explore more
GeneCentric Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GeneCentric Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when GeneCentric Therapeutics launches new products
GeneCentric Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at GeneCentric Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GeneCentric Therapeutics has new funding data
Earning: See what the market has to say on GeneCentric Therapeutics recently announced quarterly report
Check if GeneCentric Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if GeneCentric Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if GeneCentric Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined GeneCentric Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to GeneCentric Therapeutics
Compare insights from companies similar to GeneCentric Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GeneCentric Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GeneCentric Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GeneCentric Therapeutics.
GeneCentric Therapeutics financials insights
Gather financial insights about GeneCentric Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$5M
2015
Series B
$20M
2016
Private Equity
$6.1M
2020
Debt
$150K
2021
Unspecified
$4.5M
Series B
$7.5M
2025
Series C
$8M
GeneCentric Therapeutics Tech Stack
A closer look at the technologies used by GeneCentric Therapeutics
Most Recent Scoops
Funding
Funding
Event
Events
Event
Events
Executive Move
Board of Directors
Executive Move
Board of Directors
GeneCentric Therapeutics News & Media
GeneCentric Announces Series C Financing to Advance Novel Liquid Biopsy Platform for Precision Oncology
DURHAM, N.C.--(BUSINESS WIRE)-- #GeneCentric--GeneCentric Announces $8 Million Series C Financing to Advance Novel GenomicsNext Liquid Biopsy Platform for Precision OncologyGeneCentric Therapeutics Launches EXpressCT Liquid Biopsy Platform
DURHAM, N.C.--(BUSINESS WIRE)-- #GeneCentric--GeneCentric's EXpressCT liquid biopsy platform adapts RNA-based gene expression signatures to cfDNA samples to yield deeper tumor insights in cancer.GeneCentric Therapeutics Announces Publication of Clinicogenomic Results from GARNER Study in High-Risk Non-Muscle Invasive Bladder Cancer
DURHAM, N.C.--(BUSINESS WIRE)-- #GeneCentric--GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancER) study were published in Clinical Cancer Research. The GARNER study, the largest high-risk non-muscle invasive bladder cancer (HR-NMIBC) patient cohort ever assembled with both clinical and genomic detail, investigated fibroblast growthGeneCentric Therapeutics Announces American Medical Association Has Granted a PLA Code for PurIST Pancreatic Cancer Test
DURHAM, N.C.--(BUSINESS WIRE)-- #GeneCentric--AMA has granted a PLA code for PurIST, an RNA expression-based test licensed to Tempus to help inform treatment for patients with pancreatic cancer.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GeneCentric Therapeutics
Sign Up For FreeTo access detailed company insights
GeneCentric Therapeutics, Inc., a leader in gene expression biomarkers and next-generation companion diagnostic development, is based in Durham, North Carolina. The company has developed a deep pipeline of gene signatures and related diagnostic tests by parsing the complexity of tumor biology using their RNA-based Tumor and Immune Micro-Environment... Read More
